Sharp Therapeutics Corp. SHRX

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its unaudited condensed interim consolidated financial statements for the six-month period ended June 30, 2026, and related management discussion and analysis. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our H1 financial...

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed its previously announced non-brokered private placement (the "Offering") of common shares in the capital of the Company (the "Common Shares") for aggregate gross proceeds of C$1,365,000 through the issuance of 1,500,000 Common Shares at a price of C$0.91 per Common Share. The net proceeds of the

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small molecule therapies to treat genetic diseases, is pleased to announce the voting results from its annual general meeting of shareholders held on July 21, 2026 (the "Meeting").All nominees set forth in the Company's amended and restated management information circular dated June 17, 2026 (the...

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of up to C$1,365,000 (the "Offering"). The Offering will consist of common shares in the capital of the Company (the "Common Shares") priced at not less than C$0.91 per Common Share. The Company expects the Offering to close in Q3 2026..

Shareholders Must Recast Their Votes to be CountedPittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting of shareholders will be held at 10:00 a.m. (Toronto time) on July 21, 2026 (the "Meeting"), having been postponed from the initial meeting date of June 30, 2026.The Company has filed an amended and restated notice of meeting (the "Amended and Restated...

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual audited consolidated financial statements for the year ended December 31, 2025, and related management discussion and analysis ("MD&A") and annual information form. All dollar figures are in United States dollars, unless otherwise stated. Scott Sneddon, Sharp's Chief Executive Officer, stated: "Our..

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Fourth Tranche, the...

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Second Tranche, the...

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it is arranging a non-brokered private placement to raise gross proceeds of not less than US$10,000,000 (the "Offering"). The placement will consist of common shares in the capital of the Company priced at not less than US$2.50 per share. The Company expects the offering to close in the fourth quarter of.